Literature DB >> 15224033

Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.

David J Sugarbaker1, Michael T Jaklitsch, Raphael Bueno, William Richards, Jeanne Lukanich, Steven J Mentzer, Yolonda Colson, Phillip Linden, Michael Chang, Leah Capalbo, Elizabeth Oldread, Siyamek Neragi-Miandoab, Scott J Swanson, Lambros S Zellos.   

Abstract

OBJECTIVE: Extrapleural pneumonectomy for therapy of mesothelioma has been associated with significant perioperative mortality and morbidity. Postoperative complications of this procedure require a unique management approach. We developed treatment algorithms for most of the common complications of extrapleural pneumonectomy resulting in reduced mortality and hospital stay. Complications after extrapleural pneumonectomy were further analyzed to elucidate means of prevention, early detection, and treatment.
METHODS: A total of 496 patients undergoing extrapleural pneumonectomy were reviewed for mortality rates, with a subset of 328 consecutive patients between 1980 and 2000 who were examined for detailed morbidity data by using a prospective clinical database.
RESULTS: Median age was 58 years (range, 28-77 years), with a 10-day (range, 4-101 days) median length of stay. One hundred ninety-eight (60.4%) of 328 patients experienced minor and major complications, and 11 of 328 patients died, for an overall mortality rate of 3.4%. Complications included the following: atrial fibrillation (145 [44.2%]), prolonged intubation (26 [7.9%]), vocal cord paralysis (22 [6.7%]), deep vein thrombosis (21 [6.4%]), technical complications (patch dehiscence, hemorrhage, or both; 20 [6.1%]), tamponade (12 [3.6%]), acute respiratory distress syndrome (12 [3.6%]), cardiac arrest (10 [3%]), constrictive physiology (9 [2.7%]), aspiration (9 [2.7%]), renal failure (9 [2.7%]), empyema (8 [2.4%]), tracheostomy (6 [1.8%]), myocardial infarction (5 [1.5%]), pulmonary embolus (5 [1.5%]), and bronchopleural fistula (2 [0.6%]). Clinical data demonstrated the following: (1) prophylaxis for atrial fibrillation is recommended; (2) early ambulation, aspiration precautions, endoscopic assessment of the vocal cords, and avoidance of fluid overload are crucial; (3) perioperative diagnosis and aggressive management of deep vein thrombosis are important; (4) immediate reoperation and open cardiac massage are essential for relief of cardiac herniation and tamponade from cardiac patch dysfunction; (5) diaphragmatic patch dehiscence, hemorrhage, or both require immediate reoperation; (6) early signs of infection might indicate bronchopleural fistula or empyema and should be treated with thoracoscopic or open drainage and staged removal of patch material; and (7) excessive perioperative mediastinal shift is treated with a catheter placed intraoperatively.
CONCLUSION: Complications after extrapleural pneumonectomy require a unique approach to management, and mortality can be minimized by early detection and aggressive treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15224033     DOI: 10.1016/j.jtcvs.2004.02.021

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  59 in total

1.  Early mesothelioma revisited.

Authors:  Seiki Hasegawa
Journal:  Int J Clin Oncol       Date:  2012-01-11       Impact factor: 3.402

2.  Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Tristan D Yan; Momo Tin; Michael Boyer; Jocelyn McLean; Paul G Bannon; Brian C McCaughan
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

3.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

4.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Use of postoperative creatinine to predict sustained kidney injury in patients undergoing mesothelioma surgery.

Authors:  K Annette Mizuguchi; Aya Mitani; Sushrut S Waikar; Peter Ireland; Christia Panizales; Gretchen Deluke; David J Sugarbaker; Joseph V Bonventre; Gyorgy Frendl
Journal:  Clin J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 8.237

6.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

7.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

8.  Salvage therapy with topical antifungal for Aspergillus fumigatus empyema complicating extrapleural pneumonectomy.

Authors:  Manoj Purohit; Achyut Guleri; Joseph Zacharias
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-05-22

9.  Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Authors:  Nico van Zandwijk; Glen Reid; Anthony Linton; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

10.  Extrapleural pneumonectomy via a lower door open thoracotomy with reconstruction of the diaphragm and pericardium using autologous materials for mesothelioma.

Authors:  Masakazu Yoshioka; Hiroaki Nomori; Takeshi Mori; Hironori Kobayashi; Kazunori Iwatani; Koei Ikeda; Kentaro Yoshimoto
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.